Saturday 17 October 2026
Export GSK’s income statement to Excel — free account
GSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024. In the quarter to June 2026, revenue grew 5.81%, EPS fell 69.5%, free cash flow grew 54.8% and total debt rose 5.61%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
49.55
0.53
+1.08%
Follow GSK
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 30.74% | 38.52% | 39.92% | 37.41% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
8 | 8 | 9 | 8 | |
| 8.01% | 9.72% | 9.63% | 9.16% | ||
ROIC |
12.58% | 15.14% | 16.44% | 15.28% | |
Return on Tangible Assets |
89.82% | 124.42% | 105.05% | 91.88% | |
Average Days of Receivables |
88.86 | 88.94 | 86.69 | 97.18 | |
Free Cash Flow per Share |
3.81 | 3.25 | 3.19 | 3.19 | |
Free Cash Flow |
7,647.98 | 6,540.67 | 6,455.04 | 6,440.71 | |
Capital Expenditures |
(3,372.99) | (3,762.76) | (3,753.02) | (3,803.19) | |
| Other line items | |||||
Cash ROIC |
14.76% | 12.13% | 13.16% | 12.94% | |
Accounts Receivable Turnover |
4.22 | 4.36 | 4.40 | 3.92 | |
Accounts Payable Turnover |
0.62 | 0.62 | 0.60 | 0.58 | |
Inventory Turnover |
1.47 | 1.51 | 1.58 | 1.46 | |
Average Days of Payables |
579.33 | 588.64 | 622.61 | 662.34 | |
Days of Inventory on Hand |
253.75 | 252.83 | 239.80 | 258.51 | |
Tax Rate |
(0.11) | (0.15) | (0.15) | (0.14) | |
Research and Development Expense of Revenue |
27.66% | 23.61% | 23.04% | 22.41% | |
Selling, General and Administrative Expense of Revenue |
27.70% | 27.87% | 27.82% | 28.21% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 4.05% | 0.00% | |
Interest Coverage |
9.22 | 11.38 | 11.32 | 11.05 | |
Operating CF/Net income |
1.70 | 1.32 | 1.35 | 1.41 | |
Depreciation/Fixed assets |
0.33 | 0.21 | 0.25 | 0.33 | |
Capex/Depreciation |
(0.82) | (1.43) | (1.23) | (0.92) | |
Revenue per Share |
22.18 | 21.82 | 21.27 | 20.84 | |
Operating CF per Share |
5.49 | 5.12 | 5.04 | 5.08 | |
Capex per Share |
(1.68) | (1.87) | (1.85) | (1.89) | |
Capex to Sales |
0.08 | 0.09 | 0.09 | 0.09 |
Columns are period end dates